1ST Biotherapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, 1ST Biotherapeutics sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 1 currently recruiting 1 completed early-phase tilt upper half by trial count

1ST Biotherapeutics: 2 sponsored US clinical trials, 1 recruiting.

1ST Biotherapeutics sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor, with 1 trials.

Mid-pack sponsor footprint

1ST Biotherapeutics is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

What is open in the 1ST Biotherapeutics pipeline

1 recruiting of 2 indexed (50% open); 1 completed (50%).

Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).

Top condition: Advanced Solid Tumor (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

1ST Biotherapeutics: open-pipeline peers nationwide

Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

1ST Biotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%20%40%60% Total trials Recruiting share 1ST Biotherapeutics1200 Pharma3 Waves Wellness3EO Health3ive Labs60 Degrees Pharmaceuticals7 Hills PharmaAbcentraAbdullah Khan
1ST Biotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

1ST Biotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this 1ST Biotherapeutics page

2 registered trials is a research-attention snapshot, not an endorsement of 1ST Biotherapeutics or any single study.

  • 1 of 1ST Biotherapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Advanced Solid Tumor is the condition 1ST Biotherapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

1ST Biotherapeutics pipeline card: 2 registered trials from official public datasets.Report a data error.